Julie Franden
Primary Care · Meridian, IDNPI 1457652661
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 86 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 23.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $668 and has fallen 96.4% since, to $24 in 2024.
Across 86 payments — averaging $18.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$377
- AstraZeneca$189
- Lilly USA, LLC$100
- E.r. Squibb & Sons, L.L.C.$97
- Amgen$87
- Neurocrine Biosciences, Inc.$72
- plus $690 from 25 others
What the payments were for
- Food & beverage$1,612100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$1,612 in reported general payments places this provider in the 75th percentile of 48 primary care providers in Idaho.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 13 | $14,805 |
| XareltoRivaroxaban | 22 | $5,835 |
| Gabapentin | 40 | $824 |
| Duloxetine Hcl | 26 | $738 |
| Bumetanide | 11 | $727 |
| Lisinopril | 63 | $710 |
| Metoprolol Succinate | 54 | $674 |
| Levothyroxine Sodium | 54 | $591 |
| Omeprazole | 41 | $558 |
| Quetiapine Fumarate | 17 | $538 |
| Levetiracetam | 19 | $351 |
| Ondansetron OdtOndansetron | 16 | $333 |
| Atorvastatin Calcium | 28 | $324 |
| Amlodipine Besylate | 40 | $307 |
| Potassium Chloride | 32 | $301 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $48 | $14,80513 claims |
| Johnson & JohnsonXarelto | $15 | $5,83522 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 48 primary care providers in Idaho.
Other primary care in Meridian
- Rebecca BeckMeridian$1K
- Denise PeruskiMeridian$1K
- Candice AdamsMeridian$87
- Bradley RadfordIdaho Falls$8K
- Kathryn NielsenIdaho Falls$5K
- Jessica ButterfieldBoise$5K
- Teirza BristowKellogg$4K
- Lynnette KhandakerBoise$4K
- Justin RogersIdaho Falls$3K
- Billie Sue MayoNampa$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.